# Ooma Inc: financial statements, quarterly

OOMA · NYSE · CIK 1327688 · [Technology](/sectors/technology.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/ooma.md) · [Financials](/companies/ooma/financials.md) · [Filings](/companies/ooma/filings.md) · [Insiders](/companies/ooma/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ooma/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [59.9](/filings/0000950170-24-134668.md) | [61.7 d](/filings/0001327688-26-000009.md) | [62.5](/filings/0000950170-25-083284.md) | [64.1](/filings/0001327688-25-000008.md) | [65.1](/filings/0001193125-25-312961.md) | [65.1 d](/filings/0001327688-26-000009.md) | [65.0](/filings/0001327688-26-000014.md) | [66.4](/filings/0001327688-26-000020.md) | [67.6](/filings/0001193125-25-312961.md) | [74.6 d](/filings/0001327688-26-000009.md) | [81.1](/filings/0001327688-26-000014.md) | [83.2](/filings/0001327688-26-000020.md) |
| Cost of revenue | $m | [22.9](/filings/0000950170-24-134668.md) | [23.9 d](/filings/0001327688-26-000009.md) | [24.4](/filings/0000950170-25-083284.md) | [25.4](/filings/0001327688-25-000008.md) | [25.9](/filings/0001193125-25-312961.md) | [25.2 d](/filings/0001327688-26-000009.md) | [24.8](/filings/0001327688-26-000014.md) | [26.1](/filings/0001327688-26-000020.md) | [26.9](/filings/0001193125-25-312961.md) | [28.5 d](/filings/0001327688-26-000009.md) | [30.5](/filings/0001327688-26-000014.md) | [32.2](/filings/0001327688-26-000020.md) |
| Gross profit | $m | [36.9](/filings/0000950170-24-134668.md) | [37.8 d](/filings/0001327688-26-000009.md) | [38.1](/filings/0000950170-25-083284.md) | [38.7](/filings/0001327688-25-000008.md) | [39.3](/filings/0001193125-25-312961.md) | [39.9 d](/filings/0001327688-26-000009.md) | [40.2](/filings/0001327688-26-000014.md) | [40.2](/filings/0001327688-26-000020.md) | [40.7](/filings/0001193125-25-312961.md) | [46.1 d](/filings/0001327688-26-000009.md) | [50.7](/filings/0001327688-26-000014.md) | [51.0](/filings/0001327688-26-000020.md) |
| Research and development | $m | [12.5](/filings/0000950170-24-134668.md) | [13.7 d](/filings/0001327688-26-000009.md) | [13.8](/filings/0000950170-25-083284.md) | [13.6](/filings/0001327688-25-000008.md) | [14.2](/filings/0001193125-25-312961.md) | [12.6 d](/filings/0001327688-26-000009.md) | [12.4](/filings/0001327688-26-000014.md) | [12.5](/filings/0001327688-26-000020.md) | [12.1](/filings/0001193125-25-312961.md) | [13.2 d](/filings/0001327688-26-000009.md) | [15.0](/filings/0001327688-26-000014.md) | [15.5](/filings/0001327688-26-000020.md) |
| Operating income | $m | [(1.0)](/filings/0000950170-24-134668.md) | [(2.4) d](/filings/0001327688-26-000009.md) | [(2.7)](/filings/0000950170-25-083284.md) | [(1.6)](/filings/0001327688-25-000008.md) | [(2.3)](/filings/0001193125-25-312961.md) | [(0.3) d](/filings/0001327688-26-000009.md) | [(0.1)](/filings/0001327688-26-000014.md) | [0.9](/filings/0001327688-26-000020.md) | [1.3](/filings/0001193125-25-312961.md) | [2.1 d](/filings/0001327688-26-000009.md) | [3.5](/filings/0001327688-26-000014.md) | [4.0](/filings/0001327688-26-000020.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(3.0)](/filings/0000950170-24-134668.md) | [0.7 d](/filings/0001327688-26-000009.md) | [0.3](/filings/0000950170-25-083284.md) | [0.4](/filings/0001327688-25-000008.md) | [0.1](/filings/0001193125-25-312961.md) | [(0.1) d](/filings/0001327688-26-000009.md) | [0.2](/filings/0001327688-26-000014.md) | [(0.1)](/filings/0001327688-26-000020.md) | [0.1](/filings/0001193125-25-312961.md) | [(2.3) d](/filings/0001327688-26-000009.md) | [0.2](/filings/0001327688-26-000014.md) | [0.2](/filings/0001327688-26-000020.md) |
| Net income | $m | [2.3](/filings/0000950170-24-134668.md) | [(3.1) d](/filings/0001327688-26-000009.md) | [(2.1)](/filings/0001193125-25-312961.md) | [(2.1)](/filings/0001193125-25-312961.md) | [(2.4)](/filings/0001193125-25-312961.md) | [(0.3) d](/filings/0001327688-26-000009.md) | [(0.1)](/filings/0001327688-26-000020.md) | [1.3](/filings/0001327688-26-000020.md) | [1.4](/filings/0001193125-25-312961.md) | [4.0 d](/filings/0001327688-26-000009.md) | [2.6](/filings/0001327688-26-000020.md) | [3.0](/filings/0001327688-26-000020.md) |
| Diluted EPS | $ per share | [0.09](/filings/0000950170-24-134668.md) | not reported | [(0.08)](/filings/0000950170-25-083284.md) | [(0.08)](/filings/0001327688-25-000008.md) | [(0.09)](/filings/0001193125-25-312961.md) | not reported | [(0.01)](/filings/0001327688-26-000014.md) | [0.04](/filings/0001327688-26-000020.md) | [0.05](/filings/0001193125-25-312961.md) | not reported | [0.09](/filings/0001327688-26-000014.md) | [0.10](/filings/0001327688-26-000020.md) |
| Basic EPS | $ per share | [0.09](/filings/0000950170-24-134668.md) | not reported | [(0.08)](/filings/0000950170-25-083284.md) | [(0.08)](/filings/0001327688-25-000008.md) | [(0.09)](/filings/0001193125-25-312961.md) | not reported | [(0.01)](/filings/0001327688-26-000014.md) | [0.05](/filings/0001327688-26-000020.md) | [0.05](/filings/0001193125-25-312961.md) | not reported | [0.09](/filings/0001327688-26-000014.md) | [0.11](/filings/0001327688-26-000020.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-10-31) | FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [18.9](/filings/0000950170-23-068911.md) | [17.5](/filings/0000950170-25-048692.md) | [15.6](/filings/0000950170-25-083284.md) | [16.6](/filings/0000950170-24-104426.md) | [17.1](/filings/0000950170-24-134668.md) | [17.9](/filings/0001327688-26-000009.md) | [19.0](/filings/0000950170-25-083284.md) | [19.6](/filings/0001327688-25-000008.md) | [21.7](/filings/0001193125-25-312961.md) | [20.1](/filings/0001327688-26-000020.md) | [17.2](/filings/0001327688-26-000014.md) | [17.5](/filings/0001327688-26-000020.md) |
| Current assets | $m | [65.8](/filings/0000950170-23-068911.md) | [63.7](/filings/0000950170-25-048692.md) | [57.4](/filings/0000950170-24-070813.md) | [55.6](/filings/0000950170-24-104426.md) | [55.1](/filings/0000950170-24-134668.md) | [56.2](/filings/0001327688-26-000009.md) | [57.3](/filings/0000950170-25-083284.md) | [59.8](/filings/0001327688-25-000008.md) | [64.2](/filings/0001193125-25-312961.md) | [66.7](/filings/0001327688-26-000020.md) | [67.4](/filings/0001327688-26-000014.md) | [69.3](/filings/0001327688-26-000020.md) |
| Total assets | $m | [163](/filings/0000950170-23-068911.md) | [159](/filings/0000950170-25-048692.md) | [155](/filings/0000950170-24-070813.md) | [151](/filings/0000950170-24-104426.md) | [150](/filings/0000950170-24-134668.md) | [149](/filings/0001327688-26-000009.md) | [149](/filings/0000950170-25-083284.md) | [150](/filings/0001327688-25-000008.md) | [153](/filings/0001193125-25-312961.md) | [228](/filings/0001327688-26-000020.md) | [227](/filings/0001327688-26-000014.md) | [226](/filings/0001327688-26-000020.md) |
| Current liabilities | $m | [53.7](/filings/0000950170-23-068911.md) | [51.5](/filings/0000950170-25-048692.md) | [49.4](/filings/0000950170-24-070813.md) | [48.5](/filings/0000950170-24-104426.md) | [50.9](/filings/0000950170-24-134668.md) | [51.7](/filings/0001327688-26-000009.md) | [49.3](/filings/0000950170-25-083284.md) | [50.4](/filings/0001327688-25-000008.md) | [51.7](/filings/0001193125-25-312961.md) | [71.7](/filings/0001327688-26-000020.md) | [71.7](/filings/0001327688-26-000014.md) | [72.6](/filings/0001327688-26-000020.md) |
| Total liabilities | $m | [85.4](/filings/0000950170-23-068911.md) | [81.2](/filings/0000950170-25-048692.md) | [74.2](/filings/0000950170-24-070813.md) | [69.6](/filings/0000950170-24-104426.md) | [66.1](/filings/0000950170-24-134668.md) | [63.9](/filings/0001327688-26-000009.md) | [61.1](/filings/0000950170-25-083284.md) | [62.0](/filings/0001327688-25-000008.md) | [62.7](/filings/0001193125-25-312961.md) | [135](/filings/0001327688-26-000020.md) | [131](/filings/0001327688-26-000014.md) | [128](/filings/0001327688-26-000020.md) |
| Long-term debt | $m | [18.0](/filings/0000950170-23-068911.md) | [16.0](/filings/0000950170-25-048692.md) | [11.5](/filings/0000950170-24-070813.md) | [8.5](/filings/0000950170-24-104426.md) | [3.0](/filings/0000950170-24-134668.md) | [0.0](/filings/0000950170-25-048692.md) | not reported | not reported | not reported | [51.5](/filings/0001327688-26-000020.md) | [48.3](/filings/0001327688-26-000014.md) | [45.1](/filings/0001327688-26-000020.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [6.4](/filings/0001327688-26-000020.md) | [4.6](/filings/0001327688-26-000014.md) | [1.4](/filings/0001327688-26-000020.md) |
| Shareholders' equity | $m | [77.5](/filings/0000950170-24-134668.md) | [78.1](/filings/0001327688-26-000009.md) | [81.0](/filings/0001193125-25-312961.md) | [81.8](/filings/0001193125-25-312961.md) | [83.5](/filings/0001193125-25-312961.md) | [85.3](/filings/0001327688-26-000020.md) | [87.7](/filings/0001327688-26-000020.md) | [88.1](/filings/0001327688-26-000020.md) | [90.0](/filings/0001193125-25-312961.md) | [92.9](/filings/0001327688-26-000020.md) | [95.9](/filings/0001327688-26-000020.md) | [98.4](/filings/0001327688-26-000020.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1.9 d](/filings/0000950170-24-134668.md) | [5.5 d](/filings/0001327688-26-000009.md) | [3.6](/filings/0000950170-25-083284.md) | [7.1 d](/filings/0001327688-25-000008.md) | [8.1 d](/filings/0001193125-25-312961.md) | [7.8 d](/filings/0001327688-26-000009.md) | [3.7](/filings/0001327688-26-000014.md) | [6.4 d](/filings/0001327688-26-000020.md) | [6.9 d](/filings/0001193125-25-312961.md) | [10.7 d](/filings/0001327688-26-000009.md) | [6.4](/filings/0001327688-26-000014.md) | [13.1 d](/filings/0001327688-26-000020.md) |
| Capital expenditure | $m | [1.4 d](/filings/0000950170-24-134668.md) | [1.3 d](/filings/0001327688-26-000009.md) | [1.5](/filings/0000950170-25-083284.md) | [1.7 d](/filings/0001327688-25-000008.md) | [1.6 d](/filings/0001193125-25-312961.md) | [1.7 d](/filings/0001327688-26-000009.md) | [1.2](/filings/0001327688-26-000014.md) | [1.3 d](/filings/0001327688-26-000020.md) | [1.5 d](/filings/0001193125-25-312961.md) | [1.6 d](/filings/0001327688-26-000009.md) | [1.5](/filings/0001327688-26-000014.md) | [2.3 d](/filings/0001327688-26-000020.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | [1.2 d](/filings/0001193125-25-312961.md) | [2.4 d](/filings/0001327688-26-000009.md) | [2.2](/filings/0001327688-26-000014.md) | [3.2 d](/filings/0001327688-26-000020.md) | [2.8 d](/filings/0001193125-25-312961.md) | [3.4 d](/filings/0001327688-26-000009.md) | [3.3](/filings/0001327688-26-000014.md) | [2.5 d](/filings/0001327688-26-000020.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2022-10-31) | Q1 FY2024 (2023-04-30) | Q2 FY2024 (2023-07-31) | Q3 FY2024 (2023-10-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [24.6](/filings/0000950170-23-068911.md) | [25.2](/filings/0000950170-24-070813.md) | [25.9](/filings/0000950170-24-104426.md) | [26.0](/filings/0000950170-24-134668.md) | [26.2](/filings/0000950170-25-083284.md) | [26.6](/filings/0001327688-25-000008.md) | [26.8](/filings/0001193125-25-312961.md) | [27.4](/filings/0001327688-26-000014.md) | [28.1](/filings/0001327688-26-000020.md) | [28.0](/filings/0001193125-25-312961.md) | [28.1](/filings/0001327688-26-000014.md) | [28.9](/filings/0001327688-26-000020.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 27,600,000 at 2026-08-28, from the cover of the [10-Q filed 2026-09-04](/filings/0001327688-26-000020.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.